Aktuellt
SENASTE
Redeye comments on Gasporox Q4'22 report which came in lighter than expected. However, our view is that the Company is investing for sustained long-term growth and one quarter should not be viewed in isolation. Overall, we reduce our net sales 2023e-2025e by 17%-20% and reduce our Base case by 20%.
LÄS MER
